Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
EJNMMI Research
Published in: EJNMMI Research 1/2017

Open Access 01-12-2017 | Original research

Effective dose estimation for oncological and neurological PET/CT procedures

Authors: Josep M. Martí-Climent, Elena Prieto, Verónica Morán, Lidia Sancho, Macarena Rodríguez-Fraile, Javier Arbizu, María J. García-Velloso, José A. Richter

Published in: EJNMMI Research | Issue 1/2017

Login to get access

Abstract

Background

The aim of this study was to retrospectively evaluate the patient effective dose (ED) for different PET/CT procedures performed with a variety of PET radiopharmaceutical compounds.
PET/CT studies of 210 patients were reviewed including Torso (n = 123), Whole body (WB) (n = 36), Head and Neck Tumor (HNT) (n = 10), and Brain (n = 41) protocols with 18FDG (n = 170), 11C-CHOL (n = 10), 18FDOPA (n = 10), 11C-MET (n = 10), and 18F-florbetapir (n = 10). ED was calculated using conversion factors applied to the radiotracer activity and to the CT dose-length product.

Results

Total ED (mean ± SD) for Torso-11C-CHOL, Torso-18FDG, WB-18FDG, and HNT-18FDG protocols were 13.5 ± 2.2, 16.5 ± 4.5, 20.0 ± 5.6, and 15.4 ± 2.8 mSv, respectively, where CT represented 77, 62, 69, and 63% of the protocol ED, respectively. For 18FDG, 18FDOPA, 11C-MET, and 18F-florbetapir brain PET/CT studies, ED values (mean ± SD) were 6.4 ± 0.6, 4.6 ± 0.4, 5.2 ± 0.5, and 9.1 ± 0.4 mSv, respectively, and the corresponding CT contributions were 11, 14, 23, and 26%, respectively. In 18FDG PET/CT, variations in scan length and arm position produced significant differences in CT ED (p < 0.01). For dual-time-point imaging, the CT ED (mean ± SD) for the delayed scan was 3.8 ± 1.5 mSv.

Conclusions

The mean ED for body and brain PET/CT protocols with different radiopharmaceuticals ranged between 4.6 and 20.0 mSv. The major contributor to total ED for body protocols is CT, whereas for brain studies, it is the PET radiopharmaceutical.
Literature
1.
Townsend DW, Beyer T, Blodgett TM. PET/CT scanners: a hardware approach to image fusion. Semin Nucl Med. 2003;33:193–204.CrossRefPubMed
2.
Alavi A, Reivich M. Guest editorial: the conception of FDG-PET imaging. Semin Nucl Med. 2002;32:2–5.CrossRefPubMed
3.
Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480–508.CrossRefPubMed
4.
Belhocine T, Spaepen K, Dusart M, Castaigne C, Muylle K, Bourgeois P, et al. 18FDG PET in oncology: the best and the worst (review). Int J Oncol. 2006;28:1249–61.PubMed
5.
European Union. Medical radiation exposure of the European population. Part 1/2. Radiat Prot N° 180 2014:1–181.
6.
7.
Huang B, Martin Wai-Ming Law M, Khong P-L, Law MW-M, Khong P-L. Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology. 2009;251:166–74.CrossRefPubMed
8.
Willowson KP, Bailey EA, Bailey DL. A retrospective evaluation of radiation dose associated with low dose FDG protocols in whole-body PET/CT. Australas Phys Eng Sci Med. 2012;35:49–53.CrossRefPubMed
9.
Avramova-Cholakova S, Ivanova S, Petrova E, Garcheva M, Vassileva J. Patient doses from PET-CT procedures. Radiat Prot Dosimetry. 2015;165:1–4.CrossRef
10.
Houshmand S, Salavati A, Basu S, Khiewvan B, Alavi A. The role of dual and multiple time point imaging of FDG uptake in both normal and disease states. Clin Transl Imaging. 2014;2:281–93.CrossRef
11.
Matthiessen LW, Johannesen HH, Skougaard K, Gehl J, Hendel HW. Dual time point imaging fluorine-18 flourodeoxyglucose positron emission tomography for evaluation of large loco-regional recurrences of breast cancer treated with electrochemotherapy. Radiol Oncol. 2013;47:358–65.PubMedPubMedCentral
12.
Prieto E, Marti-Climent JM, Dominguez-Prado I, Garrastachu P, Diez-Valle R, Tejada S, et al. Voxel-based analysis of dual-time-point 18F-FDG PET images for brain tumor identification and delineation. J Nucl Med. 2011;52:865–72.CrossRefPubMed
13.
European Union. Diagnostic reference levels in thirty-six European countries. Part 2/2. Radiat Prot N° 180 2014:1–73.
14.
Martí-Climent JM, Prieto E, Domínguez-Prado I, García-Velloso MJ, Rodríguez-Fraile M, Arbizu J, et al. Contribution of time of flight and point spread function modeling to the performance characteristics of the PET/CT Biograph mCT scanner. Rev Esp Med Nucl Imagen Mol. 2013;32:13–21.PubMed
15.
Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.CrossRefPubMed
16.
Inoue Y, Nagahara K, Tanaka Y, Miyatake H, Hata H, Hara T. Methods of CT dose estimation in whole-body 18F-FDG PET/CT. J Nucl Med. 2015;56:695–700.CrossRefPubMed
17.
International Commission on Radiological Protection. ICRP 106 Publication. Radiation dose to patients from radiopharmaceuticals. Ann ICRP 2007;38:21–4.
18.
Tolvanen T, Yli-Kerttula T, Ujula T, Autio A, Lehikoinen P, Minn H, et al. Biodistribution and radiation dosimetry of [11C]choline: a comparison between rat and human data. Eur J Nucl Med Mol Imaging. 2010;37:874–83.CrossRefPubMed
19.
20.
Kaushik A, Jaimini A, Tripathi M, D’Souza M, Sharma R, Mishra AK, et al. Estimation of patient dose in (18)F-FDG and (18)F-FDOPA PET/CT examinations. J Cancer Res Ther. 2013;9:477–83.CrossRefPubMed
21.
Wu T-H, Chu T-C, Huang Y-H, Chen L-K, Mok S-P, Lee J-K, et al. A positron emission tomography/computed tomography (PET/CT) acquisition protocol for CT radiation dose optimization. Nucl Med Commun. 2005;26:323–30.CrossRefPubMed
22.
Quinn B, Dauer Z, Pandit-Taskar N, Schoder H, Dauer LT. Radiation dosimetry of 18F-FDG PET/CT: incorporating exam-specific parameters in dose estimates. BMC Med Imaging. 2016;16:41.CrossRefPubMedPubMedCentral
23.
Brix G, Lechel U, Glatting G, Ziegler SI, Münzing W, Müller SP, et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med. 2005;46:608–13.PubMed
24.
Jallow N, Christian PE, Sunderland J, Graham MM, Hoffman JM, Nye JA. Diagnostic reference levels of CT radiation dose in oncology whole-body PET/CT. J Nucl Med. 2015;57:238–41.CrossRefPubMed
25.
Etard C, Celier D, Roch P, Aubert B. National survey of patient doses from whole-body FDG PET-CT examinations in France in 2011. Radiat Prot Dosimetry. 2012;152:334–8.CrossRefPubMed
26.
Murano T, Minamimoto R, Senda M, Uno K, Jinnouchi S, Fukuda H, et al. Radiation exposure and risk-benefit analysis in cancer screening using FDG-PET: results of a Japanese nationwide survey. Ann Nucl Med. 2011;25:657–66.CrossRefPubMed
27.
Prieto E, Domínguez-Prado I, García-Velloso MJ, Peñuelas I, Richter JA, Martí-Climent JM. Impact of time-of-flight and point-spread-function in SUV quantification for oncological PET. Clin Nucl Med. 2013;38:103–9.CrossRefPubMed
28.
Teoh EJ, McGowan DR, Macpherson RE, Bradley KM, Gleeson FV. Phantom and clinical evaluation of the Bayesian penalized likelihood reconstruction algorithm Q.Clear on an LYSO PET/CT system. J Nucl Med. 2015;56:1447–52.CrossRefPubMedPubMedCentral
29.
Murray I, Kalemis A, Glennon J, Hasan S, Quraishi S, Beyer T, et al. Time-of-flight PET/CT using low-activity protocols: potential implications for cancer therapy monitoring. Eur J Nucl Med Mol Imaging. 2010;37:1643–53.CrossRefPubMed
30.
Tonkopi E, Ross AA, MacDonald A. CT dose optimization for whole-body PET/CT examinations. Am J Roentgenol. 2013;201:257–63.CrossRef
31.
Rausch I, Cal-González J, Dapra D, Gallowitsch HJ, Lind P, Beyer T, et al. Performance evaluation of the Biograph mCT Flow PET/CT system according to the NEMA NU2-2012 standard. EJNMMI Phys. 2015;2:26.CrossRefPubMedPubMedCentral
32.
de Margerie-Mellon C, de Bazelaire C, Montlahuc C, Lambert J, Martineau A, Coulon P, et al. Reducing radiation dose at chest CT: Comparison among model-based type iterative reconstruction, hybrid iterative reconstruction, and filtered back projection. Acad Radiol. 2016;23:1246–54.
33.
Shin HJ, Chung YE, Lee YH, Choi JY, Park MS, Kim MJ, et al. Radiation dose reduction via sinogram affirmed iterative reconstruction and automatic tube voltage modulation (CARE kV) in abdominal CT. Korean J Radiol. 2013;14:886–93.CrossRefPubMedPubMedCentral
34.
Huda W, Magill D, He W. CT effective dose per dose length product using ICRP 103 weighting factors. Med Phys. 2011;38:1261–5.CrossRefPubMed
35.
Saltybaeva N, Jafari ME, Hupfer M, Kalender WA. Estimates of effective dose for CT scans of the lower extremities. Radiology. 2014;273:153–9.CrossRefPubMed
36.
Khamwan K, Krisanachinda A, Pasawang P. The determination of patient dose from 18F-FDG PET/CT examination. Radiat Prot Dosimetry. 2010;141:50–5.CrossRefPubMed
Metadata
Title
Effective dose estimation for oncological and neurological PET/CT procedures
Authors
Josep M. Martí-Climent
Elena Prieto
Verónica Morán
Lidia Sancho
Macarena Rodríguez-Fraile
Javier Arbizu
María J. García-Velloso
José A. Richter
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2017
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-017-0272-5

Other articles of this Issue 1/2017

EJNMMI Research 1/2017 Go to the issue

Original research

44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617

Original research

The effects of segmentation algorithms on the measurement of 18F-FDG PET texture parameters in non-small cell lung cancer

Original research

Blood perfusion in osteomyelitis studied with [15O]water PET in a juvenile porcine model

Original research

TSPO imaging using the novel PET ligand [18F]GE-180: quantification approaches in patients with multiple sclerosis

Original research

Design, synthesis and evaluation in an LPS rodent model of neuroinflammation of a novel 18F-labelled PET tracer targeting P2X7

Original research

Repeatability of quantitative parameters of 18F-fluoride PET/CT and biochemical tumour and specific bone remodelling markers in prostate cancer bone metastases